Recent posts

TypePostAuthorRepliesLast updated
Blog entryRoger Bate: Eclectic booster of corporate views thiru026 weeks 3 days ago
Blog entrySeptember 2004: TACD's Future of WIPO Conference thiru026 weeks 4 days ago
Blog entryFrancis Gurry appoints Sylvie Forbin, lobbyist for Vivendi, as new head of copyright at WIPO James Love026 weeks 4 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Chimeron Bio Corporation Diane Singhroy026 weeks 5 days ago
Blog entryGates Foundation v. Teachscape: Restrictions on Patenting of Gates-Funded Inventions Andrew Goldman026 weeks 5 days ago
Blog entrySCP 24 - A fruitful discussion? Staff027 weeks 4 days ago
Book pageKEI Achievements Staff027 weeks 5 days ago
Blog entrySCP24: African Group submits revised proposal for a WIPO work program on Patents and Health thiru028 weeks 1 day ago
Blog entrySCP24: KEI statement on Patents and Health thiru028 weeks 5 days ago
Blog entryApril 28, 2016 letter regarding US Senate Finance threats over compulsory license on Novartis cancer drug patents KEI Staff028 weeks 5 days ago
PageWIPO SCCR 32 - links to KEI's reports from the meeting Manon Ress028 weeks 5 days ago
PageNews reports on Senator Hatch pressure over Colombia compulsory license on Novartis drug James Love028 weeks 5 days ago
Blog entryBriefing Call on National Institutes of Health (NIH) patent policies, 29 June 2016, 11:00 A.M. (EST) Zack Struver028 weeks 5 days ago
Blog entrySCP24: KEI statement on exceptions and limitations to patent rights thiru028 weeks 5 days ago
Blog entryStanding Committee on the Law of Patents (SCP) - GRULAC proposal - Revision of 1979 WIPO Model Law for Developing Countries thiru028 weeks 6 days ago
Blog entryColombia Issues Public Interest Declaration To Lower Price of Glivec KEI Staff029 weeks 3 days ago
Blog entryHuman Rights Council heats up during informal talks on the primacy of human rights over international trade and IP regimes thiru029 weeks 3 days ago
Blog entryS. Ward Casscells, Pentagon Medical Chief, Praised Army Role in Xtandi Development Zack Struver029 weeks 5 days ago
Blog entryUS Chamber of Commerce defends Swiss drug company charging excessive prices in Colombia James Love030 weeks 6 days ago
Blog entryNovartis complaints over public interest declaration debunked Andrew Goldman030 weeks 6 days ago
Blog entryWIPO IGC30: Questions remain on protection of genetic resources as hard decisions postponed until 2017 Staff030 weeks 6 days ago
Blog entryWHA69: Resolution WHA69.23 on CEWG follow-up charts course for WHO's work on R&D thiru030 weeks 6 days ago
Book pagePrizes to stimulate innovation James Love030 weeks 6 days ago
Blog entryObama administration blocking consensus at Human Rights Council on access to medicines resolution thiru031 weeks 22 hours ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Lentigen Technology, Inc. Diane Singhroy031 weeks 3 days ago